In subgroup analysis, coexpression of HSP90 and PI3K-p110α or expression of HSP90 along with PTEN loss showed strong prognostic significance in patients with HER2-positive cancers, but not with HER2-negative cancer. This evidence concerns the gene PTEN and cancer.